MA52946B1 - Composés - Google Patents

Composés

Info

Publication number
MA52946B1
MA52946B1 MA52946A MA52946A MA52946B1 MA 52946 B1 MA52946 B1 MA 52946B1 MA 52946 A MA52946 A MA 52946A MA 52946 A MA52946 A MA 52946A MA 52946 B1 MA52946 B1 MA 52946B1
Authority
MA
Morocco
Prior art keywords
formula
compounds
hydrogen
methods
compositions
Prior art date
Application number
MA52946A
Other languages
English (en)
Other versions
MA52946A (fr
Inventor
Pamela Brown
Michael Dawson
Mona Simonovic
Steven Boakes
Esther Duperchy
Dean Rivers
Roy Lester
Scott Coleman
Original Assignee
Spero Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spero Therapeutics Inc filed Critical Spero Therapeutics Inc
Publication of MA52946A publication Critical patent/MA52946A/fr
Publication of MA52946B1 publication Critical patent/MA52946B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé de polymyxine de formule (i) et des sels, des solvates et des formes protégées de celui-ci, des compositions pharmaceutiques comprenant les composés de formule (i), et l'utilisation des composés et des compositions dans des méthodes de traitement, tels que des méthodes pour le traitement d'infections microbiennes. Les composés de formule (i) sont représentés par la formule (i) dans laquelle -r15 est un groupe : formule (ii) et -r16 est l'hydrogène ; -r17 est l'hydrogène ; -l- est une liaison covalente ou du méthylène ; et -ar est un aryle éventuellement substitué. Les groupes -x-, -r1, -r2, -r3, -r4, et -r8 sont tels que définis dans la description.
MA52946A 2018-06-25 2019-06-25 Composés MA52946B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862689602P 2018-06-25 2018-06-25
PCT/EP2019/066819 WO2020002325A1 (fr) 2018-06-25 2019-06-25 Composés

Publications (2)

Publication Number Publication Date
MA52946A MA52946A (fr) 2021-04-28
MA52946B1 true MA52946B1 (fr) 2024-03-29

Family

ID=67107423

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52946A MA52946B1 (fr) 2018-06-25 2019-06-25 Composés

Country Status (31)

Country Link
US (3) US11459357B2 (fr)
EP (2) EP3810633B1 (fr)
JP (2) JP7488774B2 (fr)
KR (1) KR20210054500A (fr)
CN (2) CN112789287B (fr)
AR (1) AR116663A1 (fr)
AU (2) AU2019294261B2 (fr)
BR (1) BR112020026663A2 (fr)
CA (1) CA3103158A1 (fr)
CO (1) CO2020016080A2 (fr)
DK (1) DK3810633T3 (fr)
EA (1) EA202092819A1 (fr)
ES (1) ES2971732T3 (fr)
FI (1) FI3810633T3 (fr)
HR (1) HRP20240028T1 (fr)
HU (1) HUE065134T2 (fr)
IL (2) IL279620B2 (fr)
LT (1) LT3810633T (fr)
MA (1) MA52946B1 (fr)
MD (1) MD3810633T2 (fr)
MX (1) MX2020013811A (fr)
PH (1) PH12020552240A1 (fr)
PL (1) PL3810633T3 (fr)
PT (1) PT3810633T (fr)
RS (1) RS65128B1 (fr)
SG (1) SG11202012747VA (fr)
SI (1) SI3810633T1 (fr)
TW (2) TW202446783A (fr)
UA (1) UA128162C2 (fr)
WO (1) WO2020002325A1 (fr)
ZA (1) ZA202301937B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
MD3810633T2 (ro) * 2018-06-25 2024-05-31 Spero Therapeutics Inc Compuşi
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
WO2022262823A1 (fr) * 2021-06-18 2022-12-22 华南理工大学 Composé promédicament de polymyxine sensible aux radicaux libres d'oxygène actif et son utilisation
CN120574287A (zh) * 2025-06-10 2025-09-02 中国药科大学 一种抗菌肽、组合物及应用
CN120518715B (zh) * 2025-07-24 2025-10-03 中国药科大学 一种抗菌肽、药物组合物及应用
CN120699105B (zh) * 2025-08-19 2025-11-21 中国药科大学 一种氘代抗菌肽及其组合物和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
WO1988000950A2 (fr) 1986-08-06 1988-02-11 Fauchere Jean Luc Fabrication de conjugues a liaisons de covalence a partir d'un antibiotique et d'un derive non toxique de la polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (fr) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
AU2004277977B2 (en) 2003-09-30 2010-10-28 Biomechanisms Inc. Compositions and methods for treating burns
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
US7807637B2 (en) 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
HUE028271T2 (en) 2006-08-11 2016-12-28 Northern Antibiotics Oy Polymixin derivatives and their applications
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
TW201035111A (en) 2008-12-23 2010-10-01 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (fr) 2009-05-14 2010-11-18 Monash University Composés antimicrobiens
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (fr) 2010-10-21 2012-04-26 Monash University Composés antimicrobiens
WO2012168820A1 (fr) * 2011-06-08 2012-12-13 Pfizer Inc. Dérivés de polymyxine utiles en tant qu'agents antibactériens
BR112014012016A2 (pt) 2011-11-18 2017-05-16 Cantab Anti-Infectives Ltd compostos
JP6643758B2 (ja) 2013-05-22 2020-02-12 スペロ・セラピューティクス・インコーポレーテッド 異なった抗生物質と一緒の組合せ療法におけるポリミキシン誘導体及びその使用
RU2740190C2 (ru) 2014-03-11 2021-01-12 Сперо Терапьютикс, Инк. Производные полимиксина и их применение в комбинированной терапии совместно с различными антибиотиками
US10047126B2 (en) 2014-04-01 2018-08-14 Monash University Polymyxin derivatives as antimicrobial compounds
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
KR20170098821A (ko) * 2014-12-17 2017-08-30 에프. 호프만-라 로슈 아게 소르타아제를 사용한 １ 단계로의 이중 폴리펩티드 컨쥬게이션을 위한 효소 원-포트 반응
WO2016166103A1 (fr) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Dérivés de polymyxine
EP3356387B1 (fr) * 2015-09-29 2024-06-26 Monash University Composés antimicrobiens dérivés de polymyxine
AU2017285424B2 (en) * 2016-06-16 2022-08-18 International Aids Vaccine Initiative, Inc. Tuberculosis compositions and methods of treating or preventing tuberculosis
MD3810633T2 (ro) * 2018-06-25 2024-05-31 Spero Therapeutics Inc Compuşi
WO2020014501A1 (fr) 2018-07-11 2020-01-16 Cidara Therapeutics, Inc. Compositions et procédés pour le traitement d'infections bactériennes

Also Published As

Publication number Publication date
EP3810633A1 (fr) 2021-04-28
AR116663A1 (es) 2021-06-02
LT3810633T (lt) 2024-01-10
CN112789287B (zh) 2024-06-21
IL279620B2 (en) 2026-03-01
UA128162C2 (uk) 2024-04-24
WO2020002325A1 (fr) 2020-01-02
AU2024203362A1 (en) 2024-06-06
SG11202012747VA (en) 2021-01-28
CN118878638A (zh) 2024-11-01
HUE065134T2 (hu) 2024-05-28
MX2020013811A (es) 2021-03-09
HRP20240028T1 (hr) 2024-03-29
EP3810633B1 (fr) 2023-12-13
US20260103491A1 (en) 2026-04-16
DK3810633T3 (da) 2024-01-15
IL279620B1 (en) 2025-11-01
IL279620A (en) 2021-03-01
TW202446783A (zh) 2024-12-01
FI3810633T3 (fi) 2024-02-09
CA3103158A1 (fr) 2020-01-02
JP2021528449A (ja) 2021-10-21
AU2019294261B2 (en) 2024-02-29
AU2019294261A1 (en) 2021-02-04
IL323560A (en) 2025-11-01
ES2971732T3 (es) 2024-06-06
NZ771833A (en) 2024-09-27
ZA202301937B (en) 2023-09-27
RS65128B1 (sr) 2024-02-29
PT3810633T (pt) 2024-02-19
CN112789287A (zh) 2021-05-11
US11459357B2 (en) 2022-10-04
US20210246169A1 (en) 2021-08-12
US12528837B2 (en) 2026-01-20
TW202019949A (zh) 2020-06-01
PL3810633T3 (pl) 2024-04-08
MA52946A (fr) 2021-04-28
EP4316504A3 (fr) 2024-04-17
CO2020016080A2 (es) 2021-01-18
PH12020552240A1 (en) 2021-08-16
SI3810633T1 (sl) 2024-04-30
JP7488774B2 (ja) 2024-05-22
EA202092819A1 (ru) 2021-05-21
EP4316504A2 (fr) 2024-02-07
JP2024109664A (ja) 2024-08-14
KR20210054500A (ko) 2021-05-13
TWI851584B (zh) 2024-08-11
BR112020026663A2 (pt) 2021-03-23
MD3810633T2 (ro) 2024-05-31
US20230012121A1 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
MA52946B1 (fr) Composés
MA51530B1 (fr) Composés cycliques fondus
MA45020B1 (fr) Dérivés sulfonamides aromatiques
MA51620B1 (fr) Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques
MA52360B1 (fr) Dérivés de 2-amino-pyridine ou de 2-amino-pyrimidine utilisés en tant qu'inhibiteurs de kinases dépendantes des cyclines
MA63032B1 (fr) Composés contenant du nitrile pour utilisation comme médicaments
MA64509B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
MA67365B1 (fr) Dérivés de benzisoxazole sulfonamide
MA64121B1 (fr) Composés hétérocycliques utilisés comme immunomodulateurs
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA32965B1 (fr) Derives de sulfonamides
MA35601B1 (fr) Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1
MA34308B1 (fr) Triazolopyridines substituées
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
MA30911B1 (fr) Nouveaux derives de sulfonamide en tant qu'antagonistes de bradykinine
MA46101A (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
EA202092168A1 (ru) Применение фавипиравира в лечении коронавирусной инфекции
MA40523A (fr) 2-(morpholin-4-yl)-1,7-naphthyridines
CA3156303A1 (fr) Derives de 5-fluoronicotinamide et leurs utilisations
MA56883B1 (fr) Dérivés de 2-hydroxycycloalcane-1-carbamoyle
MA30912B1 (fr) Nouveaux derives de phenylsulfamoyl-benzamide en tant qu'antagonistes de la bradykinine
MA53102B1 (fr) Formulations de thiosulfate de sodium anhydre
MA50391B1 (fr) Composés d' imidazo[4,5-b]pyridine et compositions pharmaceutiques les contenant destinés à traiter les troubles inflammatoires
MA41389A1 (fr) Utilisation de sulfones tricycliques en tant que modulateurs de rory
MA43913B1 (fr) Modulateurs allostériques positifs du récepteur m1 muscarinique